<DOC>
	<DOCNO>NCT00069069</DOCNO>
	<brief_summary>This study determine maximum safe dose experimental drug E-selectin give stroke patient . E-selectin cause white blood cell call lymphocyte change prevent clot form vessel supply blood brain . The drug show effective animal model stroke . This study look safety use experimental drug nasal instillation form patient stroke transient ischemic attack ( TIA ) . Patients 45 year age old recent stroke TIA ( 30 120 day enter study ) due clot form vessel supply blood brain may eligible study . They must take least one medication prevent clot , coumadin , aspirin , ticlopidine , others . Candidates screen physical neurological examination , blood urine test , electrocardiogram ( EKG ) , echocardiogram ( ultrasound test heart ) , magnetic resonance imaging ( MRI ) brain . Participants randomly assign receive E-selectin dose level 5 , 15 , 50 microgram placebo ( nasal drop active ingredient ) . They instill small , carefully premeasured amount ( one dose ) fluid nose every day 10 day ( total 5 dos ) . This course treatment repeat two time 3-week interval . Patients follow 1 month 3 month neurologic examination blood urine test . They contact phone , fax , email two visit .</brief_summary>
	<brief_title>E-Selectin Nasal Instillation Prevent Secondary Stroke</brief_title>
	<detailed_description>In United States , stroke third leading cause death lead cause disability . Despite use antithrombotic drug secondary prevention stroke , 10 % patient experience cerebral ischemic event go stroke within 90 day ( Claiborne Johnston et al . 2003 ) . The development new treatment strategy secondary prevention stroke important issue modern medicine . There increase evidence inflammation sit endothelial activation play important role pathogenesis stroke . Control molecular inflammation sit endothelial activation achieve induction mucosal tolerance . The induction mucosal tolerance repeat low-dose intranasal administration antigen cause shift immune response proinflamatory T helper type 1 ( T ( H ) 1 ) effect anti-inflammatory immunmomodulatory regulatory T cell ( Treg ) T helper type 2 ( T ( H ) 2 ) effect sit inflammation . E-selectin adhesion molecule express activated endothelium response proinflammatory cytokine . Objective . The goal study : ( ) test whether repeat administration low-dose intranasal E-selectin safe tolerable ( b ) test whether induce mucosal tolerance compound cause shift immune response TH1 TH2 type production Treg cell . Study Population . The study population include 3-50 patient ( depend dose escalation event ) plus 0-8 replacement patient ( depend number drop out ) recent ( &gt; 30 &lt; 120 day ) occurrence type location stroke document CT MRI . The final number patient determine dose escalation plan describe may stop early accrual process adverse event arise . Since patient require make serial visit NIH clinical center , functional recovery score 0-2 modified Rankin Scale ( i.e . 0 = symptom ; 2 = slight disability : unable carry previous activity , able look affair without assistance ) require inclusion study . Study Design . This single center , Phase 1 , open label , dose escalation trial assess safety profile four dos intranasal recombinant human E-selectin . Outcome Measures . The primary goal study define maximum tolerate dose intranasal instillation recombinant human E-selection describe I Study Medications Drug Administration section . The secondary goal determine dose generate Treg cell induce immune deviation TH1 TH2 type response . The tertiary goal determine presence absence antibody human E-selectin , P- selectin , L-selectin level endothelial activation marker include von Willebrand factor , soluble E-selectin , VCAM-1 , Thrombomodulin .</detailed_description>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Occurrence type location stroke ( acute ischemic primary hemorrhagic stroke ) least 31 day , 120 day prior enrollment confirm brain imaging ( CT MRI ) . 2 . Age equal great 45 year . 3 . Modified Rankin Score 02 ( functionally independent ) time study enrollment determine clinically neurologically stable enrol investigator . EXCLUSION CRITERIA : Patients follow condition eligible participation study : 1 . Intracranial extracranial dissection , Moyamoya disease , vasculitis , radiationinduced vasculopathy , fibromuscular dysplasia , venous thrombosis . 2 . Current treatment Immunosuppressive medication include : prednisone , cyclophosphamide , cyclosporine , methotrexate , azathioprine , mycophenolate mofetil , antiCD3 moab ( Othoclone OKT3 ) , takrolimus ( FK506 ) , sirolimus , antiIL2r moab ( simulect , zenapax ) , etanercept , infliximab , lenercept , thymoglobulin ; thalidomide . 3 . Known active autoimmune disease ( RA , LE , MS , Myasthenia Gravis , etc. ) . 4 . Active cancer lymphoproliferative disease . ( except basal cell carcinoma ) 5 . Thrombocytopenia ( platelet le 100,000 ) . 6 . HIV known immunodeficiency . 7 . Recent major surgery perform within one month study enrollment . 8 . Active systemic infection , severe focal upper respiratory infection ( URI ) . 9 . Alcohol substance abuse . 10 . Dementia psychiatric problem ( determine examination , minimental status test ) prevent patient provide informed consent follow outpatient program reliably . 11 . Pregnancy ( urine pregnancy test give woman childbearing potential ) . 12 . Severe rhinopathy sinusitis . 13 . Continuing use counter , prescribe recreational intranasal drug . 14 . History NCI grade 3 epistaxis within 1 month . 15 . Exposure investigational drug within 30 day prior screen study . 16 . Planned surgery ( e.g . carotid cardiac surgery ) endovascular intervention study period study variable return baseline prevent attribution surgical complication Eselectin tolerization . 17 . Patients eligible unable tolerate brain MRI prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 23, 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>TIA</keyword>
</DOC>